TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Usability of CEREBO® to detect intracranial haemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Average Percentage of Participants at Each Session
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Average Percentage of Sessions Each Participant Completes
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Average Percentage of Hours Participants Practiced Mindfulness at Home
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in bilateral endoscopic nasal polyp score (NPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence Rate of Treatment Emergent Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Bacterial growth of face shield swab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Successful aneurysm occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Occlusion pressures (AOP, 80% and 40% of AOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Assessment of arterial flow and diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severity of Treatment-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in number of binge eating episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of adverse events related to the study drug
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of adverse events associated with the study drug
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Mean Velocity (Basal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Peak systolic velocity (Basal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Vend-diastolic velocity (Basal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Minimal stent CSA (cross-section area)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acute dose limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: COVID-19 Anxiety Syndrome Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Freedom from atrial fibrillation at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline Coma Recovery Scale - Revised
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: time on treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Visceral Sensitivity Index (VSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in postoperative forced vital capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Fried frailty criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in exhaustion
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in walking time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in muscle weakness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep Quality Scale change
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Fitbit Sleep Score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Borg Rating of Perceived Exertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of macrophage sub-populations in airway lumen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Functional status of macrophage sub-populations in airway lumen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from Baseline in Glomerular Filtration Rate (mGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pain neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: cervical joint position sense error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of MAGNETIC Foreign Body Ingestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: type of adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and severity of CSA-AKI
Endpoint domain: Adverse events/effects
Primary endpoint: Patient-reported symptomatic effect
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Device tissue coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemagglutination Inhibition (HAI) titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Solicited local and systemic post-administration reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Participant assessment of perceived positive and negative effects
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participants' overall satisfaction with the intervention
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Feasibility: overall study retention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: fMRI resting state connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in motor symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients experiencing any acute grade 3 or greater unplanned adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of preoperative radiosurgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of participants with PASI75 improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) Related to Study Drug Administration
Endpoint domain: Adverse events/effects
Primary endpoint: Participants Health-Related Quality of Life - At 6 Months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in perceived exertion
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in blood lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in The State-Trait Anxiety Inventory (STAI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-Sufficiency
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: The Student Satisfaction and Self-Confidence in Learning Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Pelvic Organ Prolapse Quantification (POP-Q) Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with clinically significant changes in hematology laboratory values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants with clinically significant changes in chemistry laboratory values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with clinically significant changes in urinalysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of patients achieving 30% reduction in daily proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percent Diameter Stenosis (DS) of side branch
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Response to treatment within 5 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left Colon Mucus Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Probable pocket depth (PPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Bleeding on probing (BoP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Damage accrual
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of hypernasality in speech
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of Patient Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Evaluation of retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean sleep latency time
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Clinical Global Impressions of Severity of Illness for sleepiness
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Efficacy of Nitric Oxide Nasal Spray
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arm lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients receiving drugs for overactive bladder
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Safety of intranasal foralumab
Endpoint domain: Adverse events/effects
Primary endpoint: immune and metabolic abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: immune and metabolic abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of VRE/CRE decolonization
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerance to simulated blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of breastfeeding self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Blood pressure response to beta-blocker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart rate response to beta-blocker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants survived at day 7
Endpoint domain: Mortality/survival
Primary endpoint: Area Under Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Luteinising Hormone (LH) Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Rate of Excellent scores on the Communication Assessment Tool
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: functional magnetic resonance imaging (fMRI) signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cerebrospinal fluid (CSF) signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum tolerated irradiation volume (MTIV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Recovery of regular menses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bilateral ovary volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroconversion rate of antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dyskinesia onset time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Emotion Regulation Checklist (ERC)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Children's Sleep Wake Scale (CSWS)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in nighttime sleep minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sleep onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sleep consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral health based Quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Post-surgical Oral health based Quality of life (24 hours after surgical exposure)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Post-surgical Oral health based Quality of life (10th day after surgical exposure)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Titer of anti-HBs ELISA antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in LA reservoir function reserve at submaximal exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: IgG antibodies against vaccine influenza antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Needle Localization Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concurrent validity of the Physical Activity Vital Sign
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concurrent validity of a submaximal cardiorespiratory fitness test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Test-retest reliability of a submaximal cardiorespiratory fitness test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone fragility in patients with hypoparathyroidism and pseudohypoparathyroidism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Physical Functioning Score (PCS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Detectable serum neural autoantibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neuronal surface antibodies-mediated autoimmune-encephalitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety of SVF injections
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in postprandial blood markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in mean intraocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of pembrolizumab and cabozantinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of tumor size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in WM on neuropsychological tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in WM-related symptoms in everyday life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Occupational Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of women screened who are eligible to participate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of eligible and enrolled women who engage in sessions and/or complete all five group sessions
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Attrition - proportion of enrolled individuals who drop out of the study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Correlation coefficient between force/thickness ratio and MRC testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oxygen saturation values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PIPP Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: comfort scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: percentage change in the number of voids every 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Muscle changes during liver disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Speech-in-noise perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of VR augmented education
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: blood glucose level at 0th minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: blood TAS level at 0th minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: blood TOS level at 0th minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Red blood cell-transfusion independence (RBC-TI) ≥ 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Accuracy of tip determination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GMTs of SARS-CoV-2 RBD-specific binding IgG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Complete remission with incomplete recovery of peripheral blood count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in postoperative cognitive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intrahepatic free glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pretracheal fat thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of PPOS in relation to Premature LH surge suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pediatric Anesthesia Emergence Delirium Scale (PAED) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention rate measure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pre-/post- survey completion rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pre-/post- biospecimen completion rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Gadolinium (Gd) - Enhancing T1 Lesion Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Aetiology of URSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anti-tumour activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Significant refractive errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in self-reported empathy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ehlers-Danlos Syndrome Symptom Battery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of manogepix
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of manogepix
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of manogepix
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety levels measured by the Spielberger State-Trait Anxiety Inventory (STAI/1-2)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in mean OPP score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dosage compliance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Medication error severity
Endpoint domain: Adverse events/effects
Primary endpoint: Renal complications of lupus disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: hospital acquired infection
Endpoint domain: Adverse events/effects
Primary endpoint: Decline rate of global longitudinal strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of 0 or 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Stutter Severity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in caregiver-rated ABC Irritability subscale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of vaccine-eligible individuals receiving the first dose of HPV vaccine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of vaccine-eligible individuals receiving the second dose of HPV vaccine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in PANSS positive subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of anesthetics drug administration error
Endpoint domain: Adverse events/effects
Primary endpoint: Number of preventable deaths
Endpoint domain: Mortality/survival
Primary endpoint: Acute alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes